Goto

Collaborating Authors

Big pharma turns to artificial intelligence to speed drug discovery, GSK signs deal

#artificialintelligence

LONDON (Reuters) - The world's leading drug companies are turning to artificial intelligence to improve the hit-and-miss business of finding new medicines, with GlaxoSmithKline unveiling a new $43 million deal in the field on Sunday. Hopkins, who used to work at Pfizer, said Exscientia's AI system could deliver drug candidates in roughly one-quarter of the time and at one-quarter of the cost of traditional approaches. "It's still to be proven, but we definitely think we should do the experiment," said John Baldoni, GSK's head of platform technology and science. "We have an obligation to reduce the cost of drugs and reduce the time it takes to get medicines to patients."


Big pharma turns to AI to speed drug discovery, GSK signs deal

#artificialintelligence

LONDON (Reuters) - The world's leading drug companies are turning to artificial intelligence to improve the hit-and-miss business of finding new medicines, with GlaxoSmithKline unveiling a new $43 million deal in the field on Sunday. Other pharmaceutical giants including Merck & Co, Johnson & Johnson and Sanofi are also exploring the potential of artificial intelligence (AI) to help streamline the drug discovery process. The aim is to harness modern supercomputers and machine learning systems to predict how molecules will behave and how likely they are to make a useful drug, thereby saving time and money on unnecessary tests. AI systems already play a central role in other high-tech areas such as the development of driverless cars and facial recognition software. "Many large pharma companies are starting to realize the potential of this approach and how it can help improve efficiencies," said Andrew Hopkins, chief executive of privately owned Exscientia, which announced the new tie-up with GSK.


Big pharma turns to artificial intelligence to speed drug discovery, GSK signs deal

#artificialintelligence

The world's leading drug companies are turning to artificial intelligence to improve the hit-and-miss business of finding new medicines, with GlaxoSmithKline unveiling a new USD 43 million deal in the field on Sunday. Other pharmaceutical giants including Merck & Co, Johnson & Johnson and Sanofi are also exploring the potential of artificial intelligence (AI) to help streamline the drug discovery process. The aim is to harness modern supercomputers and machine learning systems to predict how molecules will behave and how likely they are to make a useful drug, thereby saving time and money on unnecessary tests. AI systems already play a central role in other high-tech areas such as the development of driverless cars and facial recognition software. "Many large pharma companies are starting to realise the potential of this approach and how it can help improve efficiencies," said Andrew Hopkins, chief executive of privately owned Exscientia, which announced the new tie-up with GSK.


Big pharma turns to artificial intelligence to speed drug discovery, GSK signs deal

#artificialintelligence

LONDON (Reuters) - The world's leading drug companies are turning to artificial intelligence to improve the hit-and-miss business of finding new medicines, with GlaxoSmithKline unveiling a new $43 million deal in the field on Sunday. Other pharmaceutical giants including Merck & Co, Johnson & Johnson and Sanofi are also exploring the potential of artificial intelligence (AI) to help streamline the drug discovery process. The aim is to harness modern supercomputers and machine learning systems to predict how molecules will behave and how likely they are to make a useful drug, thereby saving time and money on unnecessary tests. AI systems already play a central role in other high-tech areas such as the development of driverless cars and facial recognition software. "Many large pharma companies are starting to realise the potential of this approach and how it can help improve efficiencies," said Andrew Hopkins, chief executive of privately owned Exscientia, which announced the new tie-up with GSK.


Is artificial intelligence the future of drug discovery? - Pharmaceutical Technology

#artificialintelligence

Increasing investments in AI indicate the benefits of applying machine learning to identify and screen potential drug candidates. The applications of artificial intelligence (AI) in healthcare are numerous, with the potential to transform key aspects of the industry, such as drug discovery. For many pharmaceutical companies, machine learning is the most important aspect of AI, with the potential to allow machines to ultimately surpass the intelligence levels of humans. Increasing investments in AI in drug discovery by big pharma suggest a truth behind the benefits of applying machine learning to identify and screen potential drug candidates. More and more, big pharma is partnering with AI-driven companies in hopes of more accurately predicting drug candidates and cutting R&D costs and time, prompting GlobalData to ask--Is AI the future of drug discovery?